Skip to Content

Join the 'Rapamune' group to help and get support from people like you.

Rapamune News

'Chemo Brain' Lasts for Months in Many Breast Cancer Survivors

Posted 11 Jan 2017 by

WEDNESDAY, Jan. 11, 2017 – "Chemo brain" – the mental fog common after breast cancer treatment – can persist for six months, new research shows. The finding comes from one of the largest studies to date to look at chemotherapy-related thinking problems that plague many women treated for breast cancer. Those problems can include memory lapses, attention issues and difficulty processing information. When researchers compared hundreds of U.S. women six months after chemotherapy ended with hundreds of healthy women, they found more than one-third of the chemotherapy group had a decline in thinking scores versus less than 15 percent of the others. "The bottom line is, this is a real problem, patients are having difficulties and we need to acknowledge it is one of the difficulties of treatment," said Dr. Patricia Ganz. Ganz is director of cancer prevention and control research at the ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Anastrozole, Breast Cancer, Metastatic, Zoladex, Letrozole, Evista, Megestrol, Megace, Herceptin, Aromasin, Afinitor

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the American Society of Nephrology, the researchers looked at data from more than 200,000 U.S. kidney transplant candidates and recipients. Along with finding that these patients are at increased risk for certain types of cancer, the investigators also identified clear patterns of risk associated with different types of treatment. However, the associations seen in the study do not prove cause-and-effect. The risk of kidney and thyroid cancers was especially high when kidney failure patients were on ... Read more

Related support groups: Cancer, Methotrexate, Renal Failure, CellCept, Gilenya, Tysabri, Imuran, Xolair, Orencia, Chronic Kidney Disease, Revlimid, Arava, Leflunomide, Azathioprine, Afinitor, Tecfidera, Mycophenolate Mofetil, Peritoneal dialysis, Benlysta, Aubagio

FDA Approves Rapamune (sirolimus) for Rare Lung Disease Lymphangioleiomyomatosis

Posted 1 Jun 2015 by

May 28, 2015 – The U.S. Food and Drug Administration today approved Rapamune (sirolimus), to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. This is the first drug approved to treat the disease. LAM is characterized by an abnormal growth of smooth muscle cells that invade lung tissues, including the airways, and blood/lymph vessels that cause destruction of the lung, resulting in airflow obstruction, and limiting the delivery of oxygen to the body. LAM is a very rare disease. According to the U.S. National Library of Medicine, only between two and five women per million women worldwide are known to have the disease. Rapamune, which is available as both a tablet and an oral solution, was originally approved in 1999 as an immunosuppressive agent to help prevent organ rejection in patients 13 years and older ... Read more

Related support groups: Sirolimus, Rapamune, Lymphangioleiomyomatosis

Grapefruit Juice May Give Boost to Cancer Treatment: Study

Posted 7 Aug 2012 by

TUESDAY, Aug. 7 – In a small study of patients with incurable cancer, drinking 8 ounces of grapefruit juice a day boosted the effect of a drug they were given during the study. Although some participants had a response, tumors did not disappear after using the drug, which is mostly used to treat conditions unrelated to cancer. The study's main finding was that grapefruit juice might allow treatment using smaller drug dosages, therefore reducing side effects and perhaps costs. Sirolimus (Rapamune) is an immunosuppressant and not approved as a cancer drug. Its primary use is to prevent rejection after kidney transplants. It is also used as a treatment for psoriasis, the researchers noted. Some early studies suggest that sirolimus may have tumor-fighting effects. Derivatives of the drug are used in kidney cancer and breast cancer. The drug, however, has what is called poor ... Read more

Related support groups: Cancer, Sirolimus, Rapamune

Organ Transplant Drug Might Treat Rapid-Aging Disease in Kids

Posted 30 Jun 2011 by

WEDNESDAY, June 29 – A drug currently used to fight rejection in organ transplant recipients may also reverse DNA cell damage in children with a rare, deadly disorder that leaves them old long before their time, a new study suggests. Researchers from the U.S. National Institutes of Health and several universities and hospitals used the antibiotic rapamycin on skin cells taken from children with Hutchinson-Gilford progeria syndrome (HGPS), which typically kills sufferers during their teenage years. About 100 cases of progeria have been documented since the disease was discovered at the turn of the 20th century. Rapamycin appeared to heighten the cells' ability to clear out a toxic protein called progerin, which causes children with progeria to develop skin and joint problems as well as advanced cardiovascular disease that quickly proves fatal. Progerin is present in small amounts in ... Read more

Related support groups: Sirolimus, Rapamune

Transplant Drug May Fight Rare Lung Disorder

Posted 17 Mar 2011 by

WEDNESDAY, March 16 – An already approved transplant-rejection drug is the first treatment to show a benefit for women with a rare lung disease that has had no cure or, until now, even a treatment. The drug, sirolimus (Rapamycin), improved both lung function and quality of life in women with lymphangioleiomyomatosis, or LAM, according to a study published online March 16 in the New England Journal of Medicine. "To have a therapy for this disease is rare and special," said the study's lead author, Dr. Francis X. McCormack, a professor and director of pulmonary, critical care and sleep medicine at the University of Cincinnati and scientific director of the LAM Foundation in Cincinnati, which helped fund the trial and also recruited participants. LAM is characterized by progressive loss of lung function from the invasion of abnormal muscle tissue that obstructs airways. According to the ... Read more

Related support groups: Sirolimus, Rapamune

FDA Medwatch Alert: Rapamune (sirolimus)

Posted 20 Feb 2003 by

Wyeth, in cooperation with FDA, notified healthcare professionals of post-marketing reports of bronchial anastomotic dehiscence, including fatal cases, in lung transplant patients treated with Rapamune in combination with tacrolimus and corticosteroids. The safety and efficacy of Rapamune as immunosuppressive therapy has not been established in lung transplant patients.[February 2003 Letter - Wyeth] PDF Format Read more

Related support groups: Rapamune

FDA Medwatch Alert: Rapamune (sirolimus)

Posted 24 Apr 2002 by

FDA notified healthcare professionals of a "Dear Health Care Provider" letter issued April 24, 2002 by Wyeth, sent to members of the American Society of Transplantation and The American Society of Transplant Surgeons. The letter informs clinicians of the risk of hepatic artery thrombosis, graft loss, and death associated with the use of Rapamune (sirolimus) in de novo liver transplantation.[April 25, 2002 Letter - Wyeth] Read more

Related support groups: Rapamune

FDA Medwatch Alert: Immunosuppressant Drugs: Required Labeling Changes

Posted 14 Jul 2009 by

Sirolimus (marketed as Rapamune), Cyclosporine (marketed as Sandimmune and generics), Cyclosporine modified (marketed as Neoral and generics), Mycophenolate mofetil (marketed as Cellcept and generics), Mycophenolic acid (marketed as Myfortic)   The FDA is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy. These immunosuppressant drugs are used to protect against the rejection of certain organ transplants. The association of BK virus-associated nephropathy has previously been reported for another immunosuppressant drug, tacrolimus (marketed as Prograf). Monitoring for this serious risk and early intervention by the health care provider is critical. Adjustments in ... Read more

Related support groups: CellCept, Myfortic, Rapamune, Gengraf

FDA Medwatch Alert: Sirolimus (marketed as Rapamune)

Posted 11 Jun 2009 by

FDA notified healthcare professionals of clinical trial data that suggest increased mortality in stable liver transplant patients after conversion from a calcineurin inhibitor (CNI)-based immunosuppressive regimen to sirolimus (Rapamune). The trial was conducted by sirolimus manufacturer, Wyeth. The Agency will continue to examine the data on mortality and other adverse events in this study, and will make further recommendations, as appropriate. The FDA is determining whether a labeling change for sirolimus is needed. In the interim, physicians should continue to use the drug’s professional labeling as a guide to therapy. See the FDA Healthcare Professional Information sheet for current FDA recommendations. [06/11/2009 - Healthcare Professional Information Sheet - FDA] Read more

Related support groups: Rapamune

Drug Shows Promise Against Childhood Epilepsy

Posted 15 Jun 2009 by

MONDAY, June 15 – A drug commonly used to prevent rejection in organ transplant patients may be effective against childhood epilepsy, animal studies suggest. The drug, rapamycin (also known as sirolimus), appears to block seizures in mice with cortical dysplasia, a brain malformation that is a common cause of childhood epilepsy and a frequent reason for pediatric epilepsy surgery, said Gabriella D'Arcangelo, an associate professor in the department of cell biology and neuroscience at Rutgers, the State University of New Jersey. "The surgery is not without risks, and while it may help control the seizures, it does not work in all cases," D'Arcangelo said in a news release from the university. "Clearly, there is a pressing need to come up with new strategies for treatment." In the study, published online in the journal Disease Models and Mechanisms, researchers tested rapamycin, a widely ... Read more

Related support groups: Epilepsy, Rapamune

Ask a Question

Further Information

Related Condition Support Groups

Lymphangioleiomyomatosis, Organ Transplant - Rejection Prophylaxis

Rapamune Patient Information at